Outcome of Board Meeting

Q1FY27 results (unaudited): Standalone: Revenue 9.3bn +23% y-y (7.6bn) PAT 0.41bn +32% y-y (0.31bn) Consolidated: Revenue 12.0bn +18% y-y (10.2bn) PAT 0.43bn +28% y-y (0.32bn) FY26 results (audited): Standalone: Revenue 32.8bn +x% y-y (prior year not stated) EBITDA 2.1bn +x% y-y (prior year not stated) EBITDA margin 6.4% (+/-x bps y-y) PAT 1.19bn +x% y-y (prior year not stated) Consolidated: Revenue 42.5bn +x% y-y (prior year not stated) EBITDA 2.5bn +x% y-y (prior year not stated) EBITDA margin 5.9% (+/-x bps y-y) PAT 1.51bn +x% y-y (prior year not stated) Dividend: Not declared Commentary: The quarter includes acquisition of Ultra Beauty Care manufacturing facility from April 1, 2026; previous periods restated for business combinations effective April 1, 2024.